Abstract
Background: In the present study, we aimed to identify and to eliminate putative cancer stem cells (CSC) within different human pancreatic cancer cell lines as well as within 5-Fluorouracil-resistant pancreatic cancer cell lines established in our laboratory. Methods: Pancreatic CSC were identified and characterized by flow cytometry, using Hoechst 33342 dye staining. CSC from 5-FU-resistant cell lines were isolated by high-speed flow cell sorting (MoFlo) and the CSC self-renewal pathways were further analyzed by RT-PCR and Western blotting. Isolated CSC within 5-FU-resistant cell lines were exposed to the cancer stem cell targeted therapeutics (RAD001, Cyclopamine) and stained for Propidium iodide and BrdU. Furthermore, isolated CSC as well as non-tumorigenic cancer cells within 5-FU-resistant cell lines were orthotopically xenografted in nude mice and the efficacy of stem-cell-targeted therapy in combination with 5-FU was investigated. Results: Flow cytometry analysis revealed a significantly high amount of CSC in all chemotherapy-resistant cell lines. Combined 5-Fluorouracil IC50 and cancer stem cell targeted therapy resulted in the reduction of tumor cell proliferation independently on 5-FU-chemoresistance status, as detected by Propidium iodide and BrdU staining. In vivo the combination of 5-FU with cancer stem cell targeted therapeutics RAD001 or Cyclopamine significantly decreased the tumorigenic potential of CSC derived from 5-FU-resistant cell lines and dramatically reduced primary pancreatic tumor volumes and weight. Conclusions: Our results demonstrate that chemotherapy-resistant cancer cells contain the increased CSC population (as compared to their parental sensitive cells) that is highly resistant to standard chemotherapy but not towards CSC-targeted therapy in vitro and in vivo. The further characterization of such cells might therefore lead to the development of new molecular and pharmaceutical therapeutics and better anti-cancer strategies.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Literatur
Ischenko I, Seeliger H, Schaffer M, Jauch KW, Bruns CJ (2008) Cancer stem cells: How can we target them? Review. Curr Med Chem 15 (30): 3171–3184
Shmelkov SV, Butler JM, Hooper AT, et al (2008) CD133 expression is not restricted to stem cells, and both CD133+ and CD133-metastatic colon cancer cells initiate tumors. J Clin Invest 118(6): 2111–2120
Zhou J, Wang CY, Liu T et al (2008) Persistence of side population cells with high drug efflux capacity in pancreatic cancer. World J Gastroenterol 14 (6): 925–930
Addla SK, Brown MD, Hart CA, Ramani VA, Clarke NW (2008) Characterization of the Hoechst 33342 side population from normal and malignant human renal epithelial cells. Am J Physiol Renal Physiol 295(3): F680–687
Harris MA, Yang H, Low BE, et al (2008) Cancer stem cells are enriched in the side population cells in a mouse model of glioma. Cancer Res 15; 68(24): 10051–10059
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer Medizin Verlag Heidelberg
About this paper
Cite this paper
Ischenko, I. et al. (2009). Tumor stem cell targeted therapy with mTOR inhibitor RAD001 and hedgehog signalling inhibitor Cyclopamine reverts chemoresistance towards 5-Fluorouracil in human pancreatic carcinoma cells. In: Schumpelick, V., Bruch, H.P., Schackert, H.K. (eds) Chirurgisches Forum und DGAV Forum 2009. Deutsche Gesellschaft für Chirurgie, vol 38. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-00625-8_22
Download citation
DOI: https://doi.org/10.1007/978-3-642-00625-8_22
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-00624-1
Online ISBN: 978-3-642-00625-8
eBook Packages: Medicine (German Language)